ArticleCardiovascular diabetology2025
Association of the triglyceride-glucose index and its combination with obesity indices with cardio-renal-metabolic multimorbidity: two decades of follow-up in the Tehran Lipid and Glucose Study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A digital marker for stratifying cardiovascular metabolic comorbidities among the middle-aged and elderly adults.PLOS digital health · 2026Article
- Association between estimated glucose disposal rate and incident heart failure in patients with coronary heart disease: a prospective cohort study.Cardiovascular diabetology · 2026Article
- The Association Between the Triglyceride-Glucose Index and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.Life (Basel, Switzerland) · 2026Article
- Predictive value of an integrated insulin resistance and lipometabolic score for cardiometabolic multimorbidity in older adults: a UK cohort study.Cardiovascular diabetology · 2026Article
- A Cross-Ethnicity Validated Machine Learning Model for the Progression of Chronic Kidney Disease in Individuals over 50 Years Old.Journal of clinical medicine · 2026Article
- The triglyceride-glucose index in chronic kidney disease: a narrative review.Frontiers in nutrition · 2026Review
- Beyond the triglyceride-glucose index, the cholesterol- high-density lipoprotein -glucose index as a superior predictor for diabetes risk in patients with major adverse cardiovascular events: dual evidence from the CHARLS database and real-world data.Frontiers in endocrinology · 2026Article
- Association between triglyceride-glucose index combined with a body shape index and atherosclerotic cardiovascular disease risk varies by glycemic status: insights from the UK Biobank.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the associations between the triglyceride-glucose (TyG) index and its obesity-related derivatives with the risk of incident cardio-renal-metabolic multimorbidity (CRMM) in a Middle Eastern adult population initially free of cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD).
methodsIn this prospective cohort analysis of 5845 Iranian adults from the Tehran Lipid and Glucose Study, we evaluated the associations of the TyG index and its combinations with body mass index (BMI), waist circumference (WC), waist-height ratio (WHtR), and waist-hip ratio (WHR) with the incidence of CRMM. Multivariable Cox proportional hazards models were used to estimate the associations between TyG indices and CRMM risk. The Wald test was used to formally compare the effect sizes of each TyG-related index with that of the TyG index in multivariable models. The predictive performance of these indices was evaluated using Harrell's C-index and the integrated discrimination improvement (IDI).
resultsOver a median follow-up of 15.3 years (IQR: 11.9-16.4), 344 individuals (5.9%) developed CRMM. Restricted cubic spline models demonstrated significant linear associations between TyG indices and CRMM risk. The corresponding HRs (95% CI) per 1-SD increase were 1.41 (1.24-1.60) for the TyG index, 1.52 (1.36-1.71) for TyG-BMI, 1.57 (1.38-1.78) for TyG-WC, 1.57 (1.38-1.78) for TyG-WHtR, and 1.42 (1.24-1.63) for TyG-WHR (all P < 0.001). The inclusion of anthropometric measures alongside the TyG index did not substantially enhance its association with CRMM risk (all P for differences ≥ 0.05). Incremental predictive performance analyses showed modest but statistically significant improvements when adding TyG and TyG-obesity indices to conventional risk factors (all P < 0.05), whereas incorporating anthropometric-based indices to a model already containing TyG did not yield additional predictive improvement (all P > 0.05). The majority of associations remained robust after adjustment for homeostatic model assessment of insulin resistance and in sensitivity analyses. The association between TyG-WHR and CRMM was more pronounced among non-obese than obese individuals (P for interaction < 0.001).
conclusionsHigher levels of TyG and TyG-obesity indices were independently associated with an increased risk of CRMM; however, incorporating obesity indices did not confer substantial improvement over the TyG index alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.